Touyun Biotech FY26 H1 profit from continuing operations rises to HK$310.8 million; revenue falls 3.3% to HK$35.4 million

• Touyun Biotech posted profit of HK$ 310.8 million, up from HK$ 28.1 million a year earlier.
• Profit attributable to shareholders climbed to HK$ 197.8 million from HK$ 11.2 million; basic EPS rose to HK 7.05 cents from HK 0.4 cents.
• Revenue edged down 3.3% to HK$ 35.4 million; gross margin fell 11.2 percentage points to 25.8%.
• Other income and gains jumped to HK$ 349.8 million from HK$ 74.8 million, driven by fair-value gains on listed and unlisted investments.
• Packaging revenue slipped to HK$ 30.6 million, while Chlamydomonas reinhardtii products revenue increased to HK$ 4.8 million; no interim dividend declared.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Touyun Biotech Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12305876), on August 28, 2026, and is solely responsible for the information contained therein.